Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer.
Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-t...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0225962 |
id |
doaj-7502390722394952b2e6c2561b0fd373 |
---|---|
record_format |
Article |
spelling |
doaj-7502390722394952b2e6c2561b0fd3732021-03-03T21:19:25ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011412e022596210.1371/journal.pone.0225962Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer.Wan-Yu ChenTseng-Cheng ChenShih-Fan LaiTony Hsiang-Kuang LiangBing-Shen HuangChun-Wei WangCurrently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-three N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT may achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Caution should be made to avoid overtreatment for this group of patients.https://doi.org/10.1371/journal.pone.0225962 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wan-Yu Chen Tseng-Cheng Chen Shih-Fan Lai Tony Hsiang-Kuang Liang Bing-Shen Huang Chun-Wei Wang |
spellingShingle |
Wan-Yu Chen Tseng-Cheng Chen Shih-Fan Lai Tony Hsiang-Kuang Liang Bing-Shen Huang Chun-Wei Wang Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer. PLoS ONE |
author_facet |
Wan-Yu Chen Tseng-Cheng Chen Shih-Fan Lai Tony Hsiang-Kuang Liang Bing-Shen Huang Chun-Wei Wang |
author_sort |
Wan-Yu Chen |
title |
Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer. |
title_short |
Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer. |
title_full |
Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer. |
title_fullStr |
Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer. |
title_full_unstemmed |
Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer. |
title_sort |
outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (n3) head and neck cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-three N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT may achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Caution should be made to avoid overtreatment for this group of patients. |
url |
https://doi.org/10.1371/journal.pone.0225962 |
work_keys_str_mv |
AT wanyuchen outcomeofbimodalitydefinitivechemoradiationdoesnotdifferfromthatoftrimodalityupfrontneckdissectionfollowedbyadjuvanttreatmentfor6cmlymphnoden3headandneckcancer AT tsengchengchen outcomeofbimodalitydefinitivechemoradiationdoesnotdifferfromthatoftrimodalityupfrontneckdissectionfollowedbyadjuvanttreatmentfor6cmlymphnoden3headandneckcancer AT shihfanlai outcomeofbimodalitydefinitivechemoradiationdoesnotdifferfromthatoftrimodalityupfrontneckdissectionfollowedbyadjuvanttreatmentfor6cmlymphnoden3headandneckcancer AT tonyhsiangkuangliang outcomeofbimodalitydefinitivechemoradiationdoesnotdifferfromthatoftrimodalityupfrontneckdissectionfollowedbyadjuvanttreatmentfor6cmlymphnoden3headandneckcancer AT bingshenhuang outcomeofbimodalitydefinitivechemoradiationdoesnotdifferfromthatoftrimodalityupfrontneckdissectionfollowedbyadjuvanttreatmentfor6cmlymphnoden3headandneckcancer AT chunweiwang outcomeofbimodalitydefinitivechemoradiationdoesnotdifferfromthatoftrimodalityupfrontneckdissectionfollowedbyadjuvanttreatmentfor6cmlymphnoden3headandneckcancer |
_version_ |
1714817471839469568 |